MedTrace Logo

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT02665234 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2019-08-16

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.

Conditions

  • Keratoconjunctivitis Sicca

Interventions

DRUG

1% Tavilermide Ophthalmic Solution

1% Tavilermide BID Dosing

DRUG

Placebo Ophthalmic Solution

Vehicle Ophthalmic Solution

Sponsors & Collaborators

  • Mimetogen Pharmaceuticals USA, Inc.

    lead INDUSTRY

Principal Investigators

  • Garth Cumberlidge, PhD · Mimetogen Pharmaceuticals USA, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-02-28
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02665234 on ClinicalTrials.gov